DE69333468D1 - Schützende antikörper induzierende antigene aus plasmodium falciparum - Google Patents

Schützende antikörper induzierende antigene aus plasmodium falciparum

Info

Publication number
DE69333468D1
DE69333468D1 DE69333468T DE69333468T DE69333468D1 DE 69333468 D1 DE69333468 D1 DE 69333468D1 DE 69333468 T DE69333468 T DE 69333468T DE 69333468 T DE69333468 T DE 69333468T DE 69333468 D1 DE69333468 D1 DE 69333468D1
Authority
DE
Germany
Prior art keywords
plasmodium falciparum
protective antibodies
inducing antigens
antigens made
antibodies inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333468T
Other languages
English (en)
Other versions
DE69333468T2 (de
Inventor
Pierre Druilhe
Hasnaq Bouharoun-Tayoun
Claude Oeuvray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of DE69333468D1 publication Critical patent/DE69333468D1/de
Application granted granted Critical
Publication of DE69333468T2 publication Critical patent/DE69333468T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69333468T 1992-10-19 1993-10-18 Schützende antikörper induzierende antigene aus plasmodium falciparum Expired - Lifetime DE69333468T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9212488A FR2697022B1 (fr) 1992-10-19 1992-10-19 Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
FR9212488 1992-10-19
PCT/FR1993/001024 WO1994009140A1 (fr) 1992-10-19 1993-10-18 Antigenes de plasmodium falciparum inducteurs d'anticorps protecteurs

Publications (2)

Publication Number Publication Date
DE69333468D1 true DE69333468D1 (de) 2004-05-06
DE69333468T2 DE69333468T2 (de) 2005-01-05

Family

ID=9434668

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333468T Expired - Lifetime DE69333468T2 (de) 1992-10-19 1993-10-18 Schützende antikörper induzierende antigene aus plasmodium falciparum

Country Status (9)

Country Link
US (4) US6017538A (de)
EP (2) EP1471150A3 (de)
AT (1) ATE263243T1 (de)
DE (1) DE69333468T2 (de)
DK (1) DK0666916T3 (de)
ES (1) ES2218520T3 (de)
FR (1) FR2697022B1 (de)
PT (1) PT666916E (de)
WO (1) WO1994009140A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US20030161840A1 (en) 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
EP1201250A1 (de) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
US20030104003A1 (en) * 2001-05-25 2003-06-05 James Anthony A. Novel surface protein of the malaria parasite plasmodium falciparum
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
NZ539509A (en) * 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
WO2004054508A2 (en) * 2002-12-12 2004-07-01 Walter Reed Army Institute Of Research Department Of The Army Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US8168166B2 (en) * 2003-12-19 2012-05-01 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
GB0329958D0 (en) * 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) * 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
EP1742619A2 (de) * 2004-05-07 2007-01-17 The President and Fellows of Harvard College Impstoff gegen pulmonale malaria
US7488489B2 (en) * 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
EP1803731A4 (de) * 2004-09-28 2011-01-26 Univ Gunma Nat Univ Corp Verfahren zur herstellung eines teilpeptids des enolaseproteins aus plasmodiumfalciparum
GB0513096D0 (en) * 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
JP4480728B2 (ja) * 2006-06-09 2010-06-16 パナソニック株式会社 Memsマイクの製造方法
KR20140070659A (ko) * 2009-05-05 2014-06-10 카딜라 핼쓰캐어 리미티드 홍역-말라리아 조합 백신
CA2809463C (en) * 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
FR2990697B1 (fr) * 2012-05-21 2015-12-18 Assist Publ Hopitaux Marseille Procede d'attenuation d'une bacterie du complexe mycobacterium tuberculosis pour la fabrication d'un vaccin contre la tuberculose
US20160320404A1 (en) 2015-03-04 2016-11-03 Sanaria Inc. Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines
WO2017024084A1 (en) * 2015-08-03 2017-02-09 University Of Washington Immunogenic compositions, antigen screening methods, and methods of generating immune responses
US10183067B1 (en) * 2017-05-05 2019-01-22 Microvax, Llc TAA/CD4OL composition/vaccine for malaria
WO2018207134A1 (en) * 2017-05-11 2018-11-15 King Abdullah University Of Science And Technology Immunogens obtained from plasmodium yoelii using quantitative sequence-linkage group selection method
US11013791B2 (en) * 2017-06-22 2021-05-25 The Government Of The United States, As Represented By The Secretary Of The Army NYVAC-based plasmodium malaria vaccine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002472A1 (fr) * 1982-12-27 1984-07-05 Pasteur Institut Fractions polypeptidiques inductrices d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant
US4632909A (en) * 1983-10-31 1986-12-30 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies which block infectivity of malarial parasites to mosquitoes
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4835259A (en) * 1984-09-14 1989-05-30 Scripps Clinic And Research Foundation Merozoite surface glycoproteins
US4978621A (en) * 1985-09-03 1990-12-18 Scripps Clinic And Research Foundation Merozoite surface antigens
WO1988000595A1 (en) * 1986-07-17 1988-01-28 Saramane Pty. Ltd. Merozoite surface antigen of plasmodium falciparum
US4897354A (en) * 1986-07-28 1990-01-30 University Of Hawaii Monoclonal antibody-specific merozoite antigens
US4957738A (en) * 1987-01-14 1990-09-18 Patarroyo Manuel E Protein copolymer malaria vaccine
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
US5225534A (en) * 1987-09-08 1993-07-06 Hoffmann-La Roche Inc. Recombinant malarial polypeptides
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5585268A (en) * 1987-12-30 1996-12-17 Behringwerke Aktiengesellschaft Malaria-specific DNA sequences, expression products thereof, and the use thereof
ATE129504T1 (de) * 1988-09-12 1995-11-15 Saramane Pty Ltd Allelische varianten von -i(plasmodium falciparum) merozoit-oberflächen-antigen.
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
FR2665365B1 (fr) * 1990-08-06 1995-04-28 Pasteur Institut Antigene de plasmodium falciparum susceptible d'induire des anticorps protecteurs - application a la vaccination.
US5993823A (en) * 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
GB9203821D0 (en) * 1992-02-22 1992-04-08 Medical Res Council Improvements in or relating to malaria vaccine
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
US7078043B2 (en) * 1999-04-20 2006-07-18 Medical Research Council Malaria vaccine
WO2001034188A1 (en) * 1999-11-12 2001-05-17 University Of Hawaii Malaria vaccine
CA2390747A1 (en) * 1999-12-09 2001-06-14 Institut Pasteur Systemic immune response induced by mucosal administration of lipid-tailed polypeptides without adjuvant
EP1201250A1 (de) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
US7306806B2 (en) * 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
US20030059436A1 (en) * 2001-03-02 2003-03-27 St. Elizabeth's Medical Center, Inc. Band 3 antigenic peptides, malaria polypeptides and uses thereof
US20030104003A1 (en) * 2001-05-25 2003-06-05 James Anthony A. Novel surface protein of the malaria parasite plasmodium falciparum
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
WO2003062374A2 (en) * 2001-11-09 2003-07-31 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
NZ539509A (en) * 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
ATE448307T1 (de) * 2003-10-24 2009-11-15 Pasteur Institut Msp-3-ähnliche genfamilie
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) * 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies

Also Published As

Publication number Publication date
EP0666916A1 (de) 1995-08-16
PT666916E (pt) 2004-08-31
DK0666916T3 (da) 2004-08-02
ES2218520T3 (es) 2004-11-16
EP0666916B1 (de) 2004-03-31
WO1994009140A1 (fr) 1994-04-28
FR2697022B1 (fr) 1994-12-16
FR2697022A1 (fr) 1994-04-22
US6949627B2 (en) 2005-09-27
EP1471150A2 (de) 2004-10-27
US20050266017A1 (en) 2005-12-01
US20040096466A1 (en) 2004-05-20
US6472519B1 (en) 2002-10-29
ATE263243T1 (de) 2004-04-15
US6017538A (en) 2000-01-25
EP1471150A3 (de) 2009-10-21
DE69333468T2 (de) 2005-01-05
US7211256B2 (en) 2007-05-01

Similar Documents

Publication Publication Date Title
DE69333468D1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
ATE267258T1 (de) Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren
ATE250083T1 (de) Lav-antigene und -peptide
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
PT759935E (pt) L1 de virus de papiloma recombinante
DK0880588T3 (da) Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium
DE69520943T2 (de) Malariapeptide
AU599889B2 (en) Cross-reactive and protective epitopes of circumsporozoite proteins
SJÖLANDER et al. Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen Pf155/RESA
Bowtell et al. Taenia taeniaeformis: Immunoprecipitation analysis of the protein antigens of oncospheres and larvae
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
Vergara et al. Multiple non-repeated epitopes on the circumsporozoite protein of Plasmodium knowlesi
MX9604182A (es) Vacunas contra parasitos helminticos.
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition